Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX HELSINKI LTD.  >  Orion Oyj    ORNBV   FI0009014377

ORION OYJ

(ORNBV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Helsinki Ltd.
01/18/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
39.14(c) 39.27(c) 38.76(c) 38.65(c) 38.58(c) Last
141 926 286 997 255 310 282 155 200 883 Volume
-0.03% +0.33% -1.30% -0.28% -0.18% Change
More quotes
Financials
Sales 2020 1 087 M 1 323 M 1 323 M
Net income 2020 234 M 285 M 285 M
Net cash position 2020 131 M 160 M 160 M
P/E ratio 2020 23,2x
Yield 2020 3,85%
Sales 2021 1 058 M 1 288 M 1 288 M
Net income 2021 207 M 252 M 252 M
Net cash position 2021 140 M 170 M 170 M
P/E ratio 2021 26,2x
Yield 2021 3,91%
Capitalization 5 420 M 6 597 M 6 595 M
EV / Sales 2020 4,87x
EV / Sales 2021 4,99x
Nbr of Employees 3 320
Free-Float 86,5%
More Financials
Company
Orion is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - generic, OTC and biosimilar drugs (46.3%); - patented prescription products (38.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - animal products (8.2%); - pharmaceutical ingredients (5.2%); - other (1.7%):... 
Sector
Pharmaceuticals
Calendar
02/09 | 11:00amErgebnisveröffentlichung
More about the company
Notations Surperformance© of Orion Oyj
Trading Rating : Investor Rating :
More Ratings
All news about ORION OYJ
01/20ORION OYJ : publishes Financial Statement Release for 2020 on Tuesday 9 February..
AQ
01/18ORION OYJ : Animal Health and Vetoquinol expand collaboration – Vetoquinol..
AQ
01/12ORION OYJ : Recommendation by the Nomination Committee concerning the Board of D..
AQ
2020NUVO PHARMACEUTICALS INC : . - Miravo Healthcare Ireland Enters into Suvexx Lice..
AQ
2020ORION OYJ : 8,242 Orion Corporation A shares converted into B shares
AQ
2020ORION OYJ : invests EUR 17 million in its production plants in Turku
PU
2020ORION OYJ : Prosecutor pressed charges against a member of Orion's Board of Dire..
PU
2020ORION OYJ : Prosecutor pressed charges against a member of Orion's Board of Dire..
AQ
2020Prosecutor pressed charges against a member of Orion's Board of Directors for..
GL
2020ORION OYJ : Composition of the Nomination Committee of Orion Corporation
PU
2020ORION OYJ : Composition of the Nomination Committee of Orion Corporation
AQ
2020Composition of the Nomination Committee of Orion Corporation
GL
2020ORION OYJ : Finnish drugmaker Orion's third-quarter profit and sales fall
RE
2020ORION OYJ : Group Interim Report 1-9/2020
PU
2020ORION OYJ : Group Interim Report 1-9/2020
AQ
More news
News in other languages on ORION OYJ
2020ORION OYJ : Veröffentlichung des Halbjahresergebnisses
2020ORION OYJ : publication des résultats semestriels
2020Les actions hésitantes, la Chine et les résultats en soutien
2019ORION OYJ : publication des résultats trimestriels
2019ORION OYJ : Veröffentlichung des Quartalsergebnisses
More news
Analyst Recommendations on ORION OYJ
More recommendations
Stock Trading Strategies
ORION OYJ - 2020
Is the distribution phase coming to an end ?
BUY
More Stock Trading Analysis
Chart ORION OYJ
Duration : Period :
Orion Oyj Technical Analysis Chart | ORNBV | FI0009014377 | MarketScreener
Technical analysis trends ORION OYJ
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Average target price 33,78 €
Last Close Price 38,58 €
Spread / Highest target 8,86%
Spread / Average Target -12,4%
Spread / Lowest Target -27,4%
EPS Revisions
Managers and Directors
NameTitle
Timo Antero Lappalainen President & Chief Executive Officer
Satu Maarit Ahomäki Senior Vice President-Commercial Operations
Jari Ilmari Karlson Chief Financial Officer & SVP-Animal Health
Sinikka Markkula Chief Information Officer
Minna Ruotsalainen Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ORION OYJ2.80%6 597
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159